Canvas Wealth Advisors LLC Has $1.18 Million Position in Qiagen N.V. $QGEN

Canvas Wealth Advisors LLC grew its stake in Qiagen N.V. (NYSE:QGEN) by 90.2% during the 2nd quarter, Holdings Channel.com reports. The firm owned 30,119 shares of the company’s stock after acquiring an additional 14,281 shares during the period. Canvas Wealth Advisors LLC’s holdings in Qiagen were worth $1,178,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

Other hedge funds also recently modified their holdings of the company. Boston Partners acquired a new stake in shares of Qiagen during the 3rd quarter worth about $179,450,000. Norges Bank bought a new position in Qiagen in the 4th quarter valued at about $166,500,000. Dimensional Fund Advisors LP bought a new position in Qiagen in the 3rd quarter valued at about $58,079,000. Price T Rowe Associates Inc. MD lifted its position in Qiagen by 12.1% during the fourth quarter. Price T Rowe Associates Inc. MD now owns 8,429,424 shares of the company’s stock worth $379,072,000 after acquiring an additional 906,589 shares during the last quarter. Finally, Deutsche Bank AG lifted its position in Qiagen by 9.7% during the fourth quarter. Deutsche Bank AG now owns 7,907,801 shares of the company’s stock worth $355,614,000 after acquiring an additional 697,342 shares during the last quarter. Institutional investors and hedge funds own 70.00% of the company’s stock.

Qiagen Stock Performance

NYSE QGEN opened at $42.65 on Wednesday. The company has a quick ratio of 2.57, a current ratio of 3.21 and a debt-to-equity ratio of 0.49. The company has a market capitalization of $8.79 billion, a P/E ratio of 21.86, a P/E/G ratio of 4.37 and a beta of 0.63. Qiagen N.V. has a 12-month low of $32.53 and a 12-month high of $57.81. The firm has a 50-day moving average price of $39.72 and a two-hundred day moving average price of $41.48.

Qiagen (NYSE:QGEN) last announced its earnings results on Wednesday, August 5th. The company reported $0.62 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $0.60 by $0.02. Qiagen had a net margin of 19.49% and a return on equity of 14.24%. The firm had revenue of $535.04 million for the quarter, compared to analyst estimates of $527.50 million. During the same quarter in the prior year, the business posted $0.60 EPS. The business’s revenue was up .2% compared to the same quarter last year. Qiagen has set its FY 2026 guidance at 2.430- EPS. Analysts anticipate that Qiagen N.V. will post 2.43 earnings per share for the current year.

Analyst Ratings Changes

QGEN has been the subject of a number of research analyst reports. TD Cowen restated a “hold” rating on shares of Qiagen in a report on Wednesday, July 15th. Berenberg Bank set a $45.50 price target on Qiagen and gave the stock a “hold” rating in a report on Tuesday, July 14th. Deutsche Bank Aktiengesellschaft reissued a “buy” rating and set a $43.00 price target on shares of Qiagen in a report on Thursday, April 30th. Jefferies Financial Group restated a “buy” rating and issued a $48.00 price target on shares of Qiagen in a research note on Thursday, August 6th. Finally, Zacks Research raised Qiagen from a “strong sell” rating to a “hold” rating in a report on Wednesday, April 29th. One analyst has rated the stock with a Strong Buy rating, four have given a Buy rating, eight have assigned a Hold rating and one has assigned a Sell rating to the company’s stock. According to data from MarketBeat.com, the stock currently has an average rating of “Hold” and a consensus target price of $43.93.

About Qiagen

Qiagen NV (NYSE: QGEN) is a global provider of sample and assay technologies designed to enable molecular testing in the fields of molecular diagnostics, applied testing, academic research and pharmaceutical development. The company’s solutions span the full workflow of nucleic acid and protein analysis, offering customers standardized kits, instruments and software tools that streamline the preparation, detection and quantification of DNA, RNA and proteins.

The company’s product portfolio includes nucleic acid extraction and purification systems, polymerase chain reaction (PCR) reagents and instrumentation, digital PCR platforms, next-generation sequencing (NGS) library‐preparation kits and proteomics solutions.